## Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest Waivers under 18 U.S.C. §208(b)(1) and under 21 U.S.C. 355(n)(4)

John R.	Teerli	ink,	M.D.
---------	--------	------	------

Committees: Endocrinologic & Metabolic Drugs and the Drug Safety and Risk

Management Advisory Committees

Meeting Dates: July 30, 2007

I acknowledge that contingent upon public disclosure of the financial interests listed below, related to the discussions of the cardiovascular ischemic/thrombotic risks of the thiazolidinediones, with focus on rosiglitazone, as presented by the FDA and GlaxoSmithKline. I am eligible to receive a waiver under 18 U.S.C. §208(b)(1) and 21 U.S.C. 355(n)(4).

Type of Interest	Nature	Magnitude
Blinded Endpoint year. Reviewer	Competing Firm	From \$10,001 to \$50,000 per
Stock in a Health Sector Mutual Fund	Health Sector Mutual Fund	Valued at between \$50,001 and 100,000.

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of these interests the waivers are not valid.

/s/	6/21/07
Signature of SGE	Date